Paper9831300
The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus.
Bretzel RG and 2 others. Exp Clin Endocrinol Diabetes, 1998. Cited by 33 papers, by iCite.
Cite this record
ConductScience Library. The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Papers, record 9831300. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9831300
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Blood Glucose | |
| Blood Pressure | |
| Glycated Hemoglobin | |
| Humans | |
| Multicenter Studies as Topic | |
| Prospective Studies | |
| Randomized Controlled Trials as Topic | |
| United Kingdom |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40512624 | VDAC1 is a target for pharmacologically induced insulin hypersecretion in β cells. | Cell Rep | 2025 | https://conductscience.org/library/papers/40512624 | PubMed |
| 37627476 | Poplar Propolis Improves Insulin Homeostasis in Non-Diabetic Insulin-Resistant Volunteers with Obesity: A Crossover Randomized Controlled Trial. | Antioxidants (Basel) | 2023 | https://conductscience.org/library/papers/37627476 | PubMed |
| 36762135 | Prescribing exercise and physical activity to treat and manage health conditions. | Ulster Med J | 2023 | https://conductscience.org/library/papers/36762135 | PubMed |
| 35196393 | ATP-Sensitive Potassium Channels in Hyperinsulinism and Type 2 Diabetes: Inconvenient Paradox or New Paradigm? | Diabetes | 2022 | https://conductscience.org/library/papers/35196393 | PubMed |
| 33317096 | Investigation of the Phytochemical Composition, Antioxidant Activity, and Methylglyoxal Trapping Effect of Galega officinalis L. Herb In Vitro. | Molecules | 2020 | https://conductscience.org/library/papers/33317096 | PubMed |
| 24678614 | Treatment of mild and moderate type-2 diabetes: open prospective trial with Hintonia latiflora extract. | Eur J Med Res | 2014 | https://conductscience.org/library/papers/24678614 | PubMed |
| 21779144 | Patient perceptions of treatment and illness when prescribed multiple medicines for co-morbid type 2 diabetes. | Diabetes Metab Syndr Obes | 2011 | https://conductscience.org/library/papers/21779144 | PubMed |
| 19684847 | Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results. | Arch Drug Inf | 2009 | https://conductscience.org/library/papers/19684847 | PubMed |
| 18959471 | Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. | PLoS Med | 2008 | https://conductscience.org/library/papers/18959471 | PubMed |
| 10776834 | Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. | Drugs | 2000 | https://conductscience.org/library/papers/10776834 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9831300
GET https://conductscience.org/api/papers/v1/9831300/authors